The Autonomic Progress Bar Motivates Treatment Completion for Patients of Stimulant Use Disorder and Cannabis Use Disorder

被引:3
|
作者
Chen, I-Chun [1 ,2 ]
Teng, Gloria [3 ]
Chen, Chur-Jen [4 ]
Lan, Tsuo-Hung [1 ,5 ]
Liu, Hung-Jen [2 ,6 ]
机构
[1] Taichung Vet Gen Hosp, Dept Psychiat, Taichung, Taiwan
[2] Natl Chung Hsing Univ, PhD Program Translat Med, Taichung, Taiwan
[3] Xiamen Univ Malaysia, Dept Math, Sepang, Selangor, Malaysia
[4] Tunghai Univ, Dept Appl Math, Taichung, Taiwan
[5] Natl Yang Ming Univ, Fac Med, Taipei, Taiwan
[6] Natl Chung Hsing Univ, Inst Mol Biol, Taichung, Taiwan
来源
FRONTIERS IN PSYCHIATRY | 2020年 / 10卷
关键词
mandatory treatment; progress bar; motivation; stimulant use disorder; time series analysis; RANDOMIZED CONTROLLED-TRIAL; SENSITIVITY;
D O I
10.3389/fpsyt.2019.00944
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: The intrinsic motivation behind the "need to complete" is more influential than external incentives. We introduced a novel progress-bar tool to motivate the completion of programs designed to treat stimulant and cannabis use disorders. We further examined the effectiveness of the progress bar's scoring approach in forecasting consistently negative urine tests. Methods: This study's participants included 568 patients with stimulant, amphetamine-type, and cannabis use disorders who were undergoing 12-month mandatory treatment programs at Taichung Veterans General Hospital in Taiwan. Patients were given scores of 1, -1, or 0 depending on whether they received negative, positive, or missing urinalysis reports, respectively. The autonomic progress bar generated weekly score totals. At the group level, score(i) donated scores from all patients for a given week (i denoted the week). Score(i) was standardized to adjusted score(i). We then conducted Autoregressive Integrated Moving Average (ARIMA) Model of time-series analyses for the adjusted score(i). Results: A total of 312 patients maintained treatment progress over the 12-month program. The autonomic score calculator totaled the shared achievements of these patients. The coefficients of the lag variables for mean (p), lag variables for residual error term (q), and number of orders for ensuring stationary (d) were estimated at p = 3, d = 4, and q = 7 for the first half of the treatment program, and were estimated at p = 2, d = 2, and q = 3 for the second half. Both models were stationary and tested as fit for prediction (p < 0.05). Sharply raised adjusted scores were predicted during the high-demand treatment phase. Discussion: This study's novel progress-bar tool effectively motivated treatment completion. It was also effective in forecasting continually negative urine tests. The tool's free open-source code makes it easy to implement among many substance-treatment services.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?
    Thomsen, Kristine Romer
    Thylstrup, Birgitte
    Kenyon, Emily A.
    Lees, Rachel
    Baandrup, Lone
    Ewing, Sarah W. Feldstein
    Freeman, Tom P.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2022, 132 : 169 - 180
  • [22] Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
    Heather Palis
    Scott MacDonald
    Jennifer Jun
    Eugenia Oviedo-Joekes
    Harm Reduction Journal, 18
  • [23] Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
    Palis, Heather
    MacDonald, Scott
    Jun, Jennifer
    Oviedo-Joekes, Eugenia
    HARM REDUCTION JOURNAL, 2021, 18 (01)
  • [24] DUAL DIAGNOSIS: HOW ADULTS DIAGNOSED WITH BIPOLAR DISORDER EXPERIENCE IN-PATIENT SUBSTANCE ABUSE TREATMENT FOR STIMULANT USE DISORDER
    van Zyl, Karina
    Geyer, Stephan
    SOCIAL WORK-MAATSKAPLIKE WERK, 2019, 55 (02): : 205 - +
  • [25] Prevalence of adults with stimulant misuse and/or stimulant use disorder in Massachusetts, USA, 2014-2021
    Barocas, Joshua A.
    Erdman, Elizabeth A.
    Westfall, Matthew Y.
    Christine, Paul J.
    Bernson, Dana
    Villani, Jennifer
    Doogan, Nathan J.
    White, Laura
    Walley, Alexander Y.
    Bettano, Amy
    Wang, Jianing
    ADDICTION, 2024,
  • [26] Starting the Discussion: A Call to Enhance Care for People With Stimulant Use Disorder
    Alves, Justin
    Rust, Victoria
    Baldwin, Marielle
    Puleikis, Logan
    Claude, Ann
    Brett, Meghan
    Labelle, Colleen T.
    Ventura, Alicia S.
    SUBSTANCE ABUSE, 2023, 44 (03) : 115 - 120
  • [28] The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal
    Brezing, Christina A.
    Levin, Frances R.
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 (01) : 173 - 194
  • [29] Cannabis use disorder and age at onset of psychosis - A study in first-episode patients
    Schimmelmann, Benno G.
    Conus, Philippe
    Cotton, Sue M.
    Kupferschmid, Stephan
    Karow, Anne
    Schultze-Lutter, Frauke
    McGorry, Patrick D.
    Lambert, Martin
    SCHIZOPHRENIA RESEARCH, 2011, 129 (01) : 52 - 56
  • [30] Treatments for Cannabis Use Disorder across the Lifespan: A Systematic Review
    Ghafouri, Mohammad
    Correa da Costa, Sabrina
    Zare Dehnavi, Ali
    Gold, Mark S.
    Rummans, Teresa A.
    BRAIN SCIENCES, 2024, 14 (03)